Literature DB >> 25593322

Regulation of sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) activity by phosphodiesterase 3A (PDE3A) in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2.

Faiyaz Ahmad1, Weixing Shen2, Fabrice Vandeput3, Nicolas Szabo-Fresnais3, Judith Krall3, Eva Degerman4, Frank Goetz5, Enno Klussmann6, Matthew Movsesian3, Vincent Manganiello2.   

Abstract

Cyclic nucleotide phosphodiesterase 3A (PDE3) regulates cAMP-mediated signaling in the heart, and PDE3 inhibitors augment contractility in patients with heart failure. Studies in mice showed that PDE3A, not PDE3B, is the subfamily responsible for these inotropic effects and that murine PDE3A1 associates with sarcoplasmic reticulum Ca(2+) ATPase 2 (SERCA2), phospholamban (PLB), and AKAP18 in a multiprotein signalosome in human sarcoplasmic reticulum (SR). Immunohistochemical staining demonstrated that PDE3A co-localizes in Z-bands of human cardiac myocytes with desmin, SERCA2, PLB, and AKAP18. In human SR fractions, cAMP increased PLB phosphorylation and SERCA2 activity; this was potentiated by PDE3 inhibition but not by PDE4 inhibition. During gel filtration chromatography of solubilized SR membranes, PDE3 activity was recovered in distinct high molecular weight (HMW) and low molecular weight (LMW) peaks. HMW peaks contained PDE3A1 and PDE3A2, whereas LMW peaks contained PDE3A1, PDE3A2, and PDE3A3. Western blotting showed that endogenous HMW PDE3A1 was the principal PKA-phosphorylated isoform. Phosphorylation of endogenous PDE3A by rPKAc increased cAMP-hydrolytic activity, correlated with shift of PDE3A from LMW to HMW peaks, and increased co-immunoprecipitation of SERCA2, cav3, PKA regulatory subunit (PKARII), PP2A, and AKAP18 with PDE3A. In experiments with recombinant proteins, phosphorylation of recombinant human PDE3A isoforms by recombinant PKA catalytic subunit increased co-immunoprecipitation with rSERCA2 and rat rAKAP18 (recombinant AKAP18). Deletion of the recombinant human PDE3A1/PDE3A2 N terminus blocked interactions with recombinant SERCA2. Serine-to-alanine substitutions identified Ser-292/Ser-293, a site unique to human PDE3A1, as the principal site regulating its interaction with SERCA2. These results indicate that phosphorylation of human PDE3A1 at a PKA site in its unique N-terminal extension promotes its incorporation into SERCA2/AKAP18 signalosomes, where it regulates a discrete cAMP pool that controls contractility by modulating phosphorylation-dependent protein-protein interactions, PLB phosphorylation, and SERCA2 activity.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  A-kinase Anchoring Protein (AKAP); Cyclic AMP (cAMP); Cyclic Nucleotide Phosphodiesterase; Immunohistochemistry; PDE3A; Phospholamban; Protein Kinase A (PKA); SERCA2; Subcellular Fractionation

Mesh:

Substances:

Year:  2015        PMID: 25593322      PMCID: PMC4358103          DOI: 10.1074/jbc.M115.638585

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Protein kinase A phosphorylation of human phosphodiesterase 3B promotes 14-3-3 protein binding and inhibits phosphatase-catalyzed inactivation.

Authors:  Daniel Palmer; Sandra L Jimmo; Daniel R Raymond; Lindsay S Wilson; Rhonda L Carter; Donald H Maurice
Journal:  J Biol Chem       Date:  2007-01-25       Impact factor: 5.157

2.  Plasma membrane cyclic nucleotide phosphodiesterase 3B (PDE3B) is associated with caveolae in primary adipocytes.

Authors:  Rebecka Nilsson; Faiyaz Ahmad; Karl Swärd; Ulrika Andersson; Marie Weston; Vincent Manganiello; Eva Degerman
Journal:  Cell Signal       Date:  2006-02-28       Impact factor: 4.315

3.  Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum.

Authors:  Y Shakur; K Takeda; Y Kenan; Z X Yu; G Rena; D Brandt; M D Houslay; E Degerman; V J Ferrans; V C Manganiello
Journal:  J Biol Chem       Date:  2000-12-08       Impact factor: 5.157

Review 4.  cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling.

Authors:  Miles D Houslay; George S Baillie; Donald H Maurice
Journal:  Circ Res       Date:  2007-04-13       Impact factor: 17.367

5.  Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB.

Authors:  Faiyaz Ahmad; Rebecka Lindh; Yan Tang; Marie Weston; Eva Degerman; Vincent C Manganiello
Journal:  Biochem J       Date:  2007-06-01       Impact factor: 3.857

Review 6.  Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart.

Authors:  Chen Yan; Clint L Miller; Jun-ichi Abe
Journal:  Circ Res       Date:  2007-03-02       Impact factor: 17.367

7.  Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice.

Authors:  Bing Sun; Haiquan Li; Yasmin Shakur; James Hensley; Steve Hockman; Junichi Kambayashi; Vincent C Manganiello; Yongge Liu
Journal:  Cell Signal       Date:  2007-04-06       Impact factor: 4.315

8.  Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes.

Authors:  Fabrice Vandeput; Sharon L Wolda; Judith Krall; Ryan Hambleton; Lothar Uher; Kim N McCaw; Przemyslaw B Radwanski; Vincent Florio; Matthew A Movsesian
Journal:  J Biol Chem       Date:  2007-08-28       Impact factor: 5.157

9.  AKAP complex regulates Ca2+ re-uptake into heart sarcoplasmic reticulum.

Authors:  Birgitte Lygren; Cathrine Rein Carlson; Katja Santamaria; Valentina Lissandron; Theresa McSorley; Jessica Litzenberg; Dorothea Lorenz; Burkhard Wiesner; Walter Rosenthal; Manuela Zaccolo; Kjetil Taskén; Enno Klussmann
Journal:  EMBO Rep       Date:  2007-09-28       Impact factor: 8.807

10.  Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells.

Authors:  Eduard Stefan; Burkhard Wiesner; George S Baillie; Rustam Mollajew; Volker Henn; Dorothea Lorenz; Jens Furkert; Katja Santamaria; Pavel Nedvetsky; Christian Hundsrucker; Michael Beyermann; Eberhard Krause; Peter Pohl; Irene Gall; Andrew N MacIntyre; Sebastian Bachmann; Miles D Houslay; Walter Rosenthal; Enno Klussmann
Journal:  J Am Soc Nephrol       Date:  2006-11-29       Impact factor: 10.121

View more
  27 in total

1.  Basal Spontaneous Firing of Rabbit Sinoatrial Node Cells Is Regulated by Dual Activation of PDEs (Phosphodiesterases) 3 and 4.

Authors:  Tatiana M Vinogradova; Syevda Sirenko; Yevgeniya O Lukyanenko; Dongmei Yang; Kirill V Tarasov; Alexey E Lyashkov; Nevin J Varghese; Yue Li; Khalid Chakir; Bruce Ziman; Edward G Lakatta
Journal:  Circ Arrhythm Electrophysiol       Date:  2018-06

2.  Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12.

Authors:  Xiaoyun Wu; Gavin R Schnitzler; Galen F Gao; Brett Diamond; Andrew R Baker; Bethany Kaplan; Kaylyn Williamson; Lindsay Westlake; Selena Lorrey; Timothy A Lewis; Colin W Garvie; Martin Lange; Sikander Hayat; Henrik Seidel; John Doench; Andrew D Cherniack; Charlotte Kopitz; Matthew Meyerson; Heidi Greulich
Journal:  J Biol Chem       Date:  2020-01-31       Impact factor: 5.157

3.  AKAP18:PKA-RIIα structure reveals crucial anchor points for recognition of regulatory subunits of PKA.

Authors:  Frank Götz; Yvette Roske; Maike Svenja Schulz; Karolin Autenrieth; Daniela Bertinetti; Katja Faelber; Kerstin Zühlke; Annika Kreuchwig; Eileen J Kennedy; Gerd Krause; Oliver Daumke; Friedrich W Herberg; Udo Heinemann; Enno Klussmann
Journal:  Biochem J       Date:  2016-04-21       Impact factor: 3.857

4.  A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction.

Authors:  Si Chen; Yishuai Zhang; Janet K Lighthouse; Deanne M Mickelsen; Jiangbin Wu; Peng Yao; Eric M Small; Chen Yan
Journal:  Circulation       Date:  2019-12-05       Impact factor: 29.690

Review 5.  Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.

Authors:  Grace E Kim; David A Kass
Journal:  Handb Exp Pharmacol       Date:  2017

6.  Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure.

Authors:  Nisha A Gilotra; Adam D DeVore; Thomas J Povsic; Allison G Hays; Virginia S Hahn; Tolu A Agunbiade; Allison DeLong; Andrew Satlin; Richard Chen; Robert Davis; David A Kass
Journal:  Circ Heart Fail       Date:  2021-08-31       Impact factor: 10.447

7.  Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2015-09-23       Impact factor: 5.000

Review 8.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

Review 9.  An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases.

Authors:  Si Chen; Chen Yan
Journal:  Expert Opin Drug Discov       Date:  2020-09-21       Impact factor: 6.098

10.  Compartmentation of β2 -adrenoceptor stimulated cAMP responses by phosphodiesterase types 2 and 3 in cardiac ventricular myocytes.

Authors:  Michael W Rudokas; John P Post; Alejandra Sataray-Rodriguez; Rinzhin T Sherpa; Karni S Moshal; Shailesh R Agarwal; Robert D Harvey
Journal:  Br J Pharmacol       Date:  2021-02-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.